Complications Associated with Mohs Micrographic Surgery: Data from the Nationwide Prospective Cohort REGESMOHS.

Dermatology (Basel, Switzerland) Pub Date : 2022-01-01 Epub Date: 2021-08-11 DOI:10.1159/000517010
Verónica Ruiz-Salas, Onofre Sanmartin-Jiménez, Joan R Garcés, Eva Vilarrasa, Román Miñano-Medrano, Begoña Escutia-Muñoz, Ángeles Flórez-Menéndez, Juan L Artola-Igarza, Alberto Alfaro-Rubio, Pedro Redondo, Yolanda Delgado-Jiménez, Julia Sánchez-Schmidt, Irati Allende-Markixana, Beatriz García Bracamonte, Pablo de la Cueva-Dobao, Cristina Ciudad, Lucía Carnero-González, Hugo Vázquez-Veiga, Pedro Sánchez-Sambucety, José Luis Estebaranz, Rafael Botella-Estrada, Beatriz González-Sixto, Antonio Martorell, Victoriano Morales-Gordillo, Agustí Toll-Abelló, Matías Mayor-Arenal, Ricardo Suárez-Fernández, Laura Sainz-Gaspar, Miguel A Descalzo, Ignacio Garcia-Doval
{"title":"Complications Associated with Mohs Micrographic Surgery: Data from the Nationwide Prospective Cohort REGESMOHS.","authors":"Verónica Ruiz-Salas,&nbsp;Onofre Sanmartin-Jiménez,&nbsp;Joan R Garcés,&nbsp;Eva Vilarrasa,&nbsp;Román Miñano-Medrano,&nbsp;Begoña Escutia-Muñoz,&nbsp;Ángeles Flórez-Menéndez,&nbsp;Juan L Artola-Igarza,&nbsp;Alberto Alfaro-Rubio,&nbsp;Pedro Redondo,&nbsp;Yolanda Delgado-Jiménez,&nbsp;Julia Sánchez-Schmidt,&nbsp;Irati Allende-Markixana,&nbsp;Beatriz García Bracamonte,&nbsp;Pablo de la Cueva-Dobao,&nbsp;Cristina Ciudad,&nbsp;Lucía Carnero-González,&nbsp;Hugo Vázquez-Veiga,&nbsp;Pedro Sánchez-Sambucety,&nbsp;José Luis Estebaranz,&nbsp;Rafael Botella-Estrada,&nbsp;Beatriz González-Sixto,&nbsp;Antonio Martorell,&nbsp;Victoriano Morales-Gordillo,&nbsp;Agustí Toll-Abelló,&nbsp;Matías Mayor-Arenal,&nbsp;Ricardo Suárez-Fernández,&nbsp;Laura Sainz-Gaspar,&nbsp;Miguel A Descalzo,&nbsp;Ignacio Garcia-Doval","doi":"10.1159/000517010","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Large prospective studies on the safety of Mohs micrographic (MMS) surgery are scarce, and most focus on a single type of surgical adverse event. Mid-term scar alterations and functional loss have not been described.</p><p><strong>Objectives: </strong>To describe the risk of MMS complications and the risk factors for them.</p><p><strong>Methods: </strong>A nationwide prospective cohort collected all adverse events on consecutive patients in 22 specialised centres. We used multilevel mixed-effects logistic regression to find out factors associated with adverse events.</p><p><strong>Results: </strong>5,017 patients were included, with 14,421 patient-years of follow-up. 7.0% had some perioperative morbidity and 6.5% had mid-term and scar-related complications. The overall risk of complications was mainly associated with use of antiaggregant/anticoagulant and larger tumours, affecting deeper structures, not reaching a tumour-free border, and requiring complex repair. Age and outpatient setting were not linked to the incidence of adverse events. Risk factors for haemorrhage (0.9%) were therapy with antiaggregant/anticoagulants, tumour size, duration of surgery, and unfinished surgery. Wound necrosis (1.9%) and dehiscence (1.0%) were associated with larger defects and complex closures. Immunosuppression was only associated with an increased risk of necrosis. Surgeries reaching deeper structures, larger tumours and previous surgical treatments were associated with wound infection (0.9%). Aesthetic scar alterations (5.4%) were more common in younger patients, with larger tumours, in H-area, and in flap and complex closures. Risk factors for functional scar alterations (1.7%) were the need for general anaesthesia, larger tumours that had received previous surgery, and flaps or complex closures.</p><p><strong>Conclusions: </strong>MMS shows a low risk of complications. Most of the risk factors for complications were related to tumour size and depth, and the resulting need for complex surgery. Antiaggregant/anticoagulant intake was associated with a small increase in the risk of haemorrhage, that probably does not justify withdrawal. Age and outpatient setting were not linked to the risk of adverse events.</p>","PeriodicalId":144585,"journal":{"name":"Dermatology (Basel, Switzerland)","volume":" ","pages":"320-328"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology (Basel, Switzerland)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000517010","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/8/11 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4

Abstract

Background: Large prospective studies on the safety of Mohs micrographic (MMS) surgery are scarce, and most focus on a single type of surgical adverse event. Mid-term scar alterations and functional loss have not been described.

Objectives: To describe the risk of MMS complications and the risk factors for them.

Methods: A nationwide prospective cohort collected all adverse events on consecutive patients in 22 specialised centres. We used multilevel mixed-effects logistic regression to find out factors associated with adverse events.

Results: 5,017 patients were included, with 14,421 patient-years of follow-up. 7.0% had some perioperative morbidity and 6.5% had mid-term and scar-related complications. The overall risk of complications was mainly associated with use of antiaggregant/anticoagulant and larger tumours, affecting deeper structures, not reaching a tumour-free border, and requiring complex repair. Age and outpatient setting were not linked to the incidence of adverse events. Risk factors for haemorrhage (0.9%) were therapy with antiaggregant/anticoagulants, tumour size, duration of surgery, and unfinished surgery. Wound necrosis (1.9%) and dehiscence (1.0%) were associated with larger defects and complex closures. Immunosuppression was only associated with an increased risk of necrosis. Surgeries reaching deeper structures, larger tumours and previous surgical treatments were associated with wound infection (0.9%). Aesthetic scar alterations (5.4%) were more common in younger patients, with larger tumours, in H-area, and in flap and complex closures. Risk factors for functional scar alterations (1.7%) were the need for general anaesthesia, larger tumours that had received previous surgery, and flaps or complex closures.

Conclusions: MMS shows a low risk of complications. Most of the risk factors for complications were related to tumour size and depth, and the resulting need for complex surgery. Antiaggregant/anticoagulant intake was associated with a small increase in the risk of haemorrhage, that probably does not justify withdrawal. Age and outpatient setting were not linked to the risk of adverse events.

莫氏显微摄影手术相关并发症:来自全国前瞻性队列REGESMOHS的数据。
背景:关于莫氏显微摄影(MMS)手术安全性的大型前瞻性研究很少,而且大多数集中在单一类型的手术不良事件上。中期疤痕改变和功能丧失尚未描述。目的:探讨MMS并发症的危险因素。方法:一个全国性的前瞻性队列收集了22个专科中心连续患者的所有不良事件。我们使用多水平混合效应逻辑回归找出与不良事件相关的因素。结果:共纳入5017例患者,随访14421例患者年。7.0%有围手术期并发症,6.5%有中期及疤痕相关并发症。并发症的总体风险主要与使用抗聚集/抗凝血剂和较大的肿瘤、影响更深的结构、未达到无肿瘤边界和需要复杂的修复有关。年龄和门诊情况与不良事件的发生率无关。出血的危险因素(0.9%)是抗凝/抗凝治疗、肿瘤大小、手术时间和未完成手术。伤口坏死(1.9%)和裂开(1.0%)与较大的缺损和复杂的闭合有关。免疫抑制仅与坏死风险增加相关。手术触及更深的结构,更大的肿瘤和既往手术治疗与伤口感染相关(0.9%)。美观性疤痕改变(5.4%)在年轻、肿瘤较大、h区、皮瓣和复杂闭合的患者中更为常见。功能性疤痕改变的危险因素(1.7%)是需要全麻,以前接受过手术的较大肿瘤,皮瓣或复杂闭合。结论:MMS并发症风险低。大多数并发症的危险因素与肿瘤的大小和深度有关,因此需要进行复杂的手术。抗凝血剂/抗凝血剂的摄入与出血风险的小幅增加有关,这可能不能证明停药是正当的。年龄和门诊情况与不良事件的风险无关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信